Company intelligence / Profile preview

AmDx PrognostX

Kentucky, United Statesamdx.co ↗

Ownership: Private
Development stage: Other

Overview

Studies on their chronic kidney disease diagnostic have returned promising results so far. The product has been licensed by AmDx to enhance its pipeline. Clinical launch planned for 2024 with ongoing/forthcoming FDA trials.

Therapeutic areas: NeurologyEndocrinologyCardiovascularNephrology
Modalities: ImmunoassayIn vitro diagnostic test
Industry: Protein Biomarker Diagnostics

Partnerships

Strategic partnerships with universities including University of KentuckyConsults with universities and other biotech companies

Beyond the preview

Go deeper on AmDx PrognostX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AmDx PrognostX.

Explore the full profile